[mfn_before_post] “We have advanced our project pipeline significantly during the second quarter. The immuno-oncology antibody ATOR-1017 mov ...
Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our
cookie policy.